Skye Bioscience
SKYE | NASDAQ
$1.06
-$0.03 (-2.75%)
At close: Nov 16, 2026, 4:00 PM ET
$1.08
+$0.02 (+1.82%)
After-hours:
Nov 16, 2026, 7:59 PM ET
Skye Bioscience Company Profile
Company profile explainedCompany Profile
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
Key Executives
| Name | Position |
|---|---|
| Punit S. Dhillon | President, CEO, Principal Financial & Accounting Officer & Director |
| John Sharp | CFO and Principal Financial & Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 28, 2026 | PRER14A | Filing |
| Oct 26, 2026 | PREM14A | Filing |
| Oct 14, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Sep 24, 2026 | 4 | Filing |
| Sep 24, 2026 | SC 13D/A | [Amend] Filing |
| Sep 24, 2026 | 4 | Filing |
| Sep 18, 2026 | 4 | Filing |
| Sep 18, 2026 | 4 | Filing |
| Sep 11, 2026 | DEFA14A | Filing |
| Sep 11, 2026 | 8-K | Current Report |
Skye Bioscience
| Country | United States |
| IPO Date | Jan 6, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Punit Dhillon |
Contact Details
11250 El Camino Real San Diego,
California 92130 United States
Stock Details
| Ticker Symbol | SKYE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001516551 |
| CUSIP Number | 83086J309 |
| ISIN Number | US83086J3095 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove SKYE